Will the price of bimetinib/bemetinib change significantly after it is included in medical insurance?

Binimetinib is a MEK inhibitor drug that has attracted much attention in the field of global tumor targeted therapy. It is mainly used in combination treatment regimens for advanced or metastatic melanoma harboring BRAF V600 mutations, and is usually used in combination with the BRAF inhibitor canafenib (Encorafenib). As a drug targeting the MEK signaling pathway, bimetinib shows good therapeutic prospects in some tumors with high mutation rates by regulating cell proliferation pathways. Although it has not yet been officially launched in mainland China, it has been approved in Europe, the United States, Australia and other countries for many years, and has been included in clinical treatment guidelines in many countries.

Regarding whether bimetinib has been included in medical insurance and whether the price has changed significantly, there is currently no original version of the drug in China that has officially entered the national medical insurance catalog. Because bimetinib has not yet been approved for marketing in China, there is no clear medical insurance payment standard for bimetinib in China. Therefore, the current question of "whether prices fluctuate greatly after medical insurance" does not apply in the Chinese context. However, judging from overseas experience, once similar high-priced targeted drugs are included in medical insurance or medical assistance projects, patients' financial burden can be significantly alleviated. For example, in the United States, some commercial insurances can cover most of the cost of bimetinib, and also provide charitable subsidies or patient assistance programs, making the out-of-pocket amount much lower than the original price of the drug.

If bimetinib is approved by China's State Food and Drug Administration and included in medical insurance in the future, it can be expected that its price will be compressed through the medical insurance negotiation mechanism, thereby gradually transitioning from the original high import pricing to a drug with higher domestic accessibility. Judging from the experience of China’s medical insurance negotiation mechanism, the price reduction of many imported targeted drugs can reach 50% or more after being included in medical insurance, which is of great significance to patients who take medicine for a long time.

Reference materials:https://go.drugbank.com/drugs/DB11967